NIKKEI 225
38,073.98 -128.42 (-0.34%) HANG SENG
18,537.81 +223.91 (+1.22%) CRUDE OIL
79.61 +0.35 (+0.44%) GOLD FUTURES
2,353.90 +13.60 (+0.58%) DOW
39,387.76 +331.36 (+0.85%) Bitcoin GBP
49,990.98 +1,086.20 (+2.22%)
Qiagen N.V. (0RLT.IL)
| Previous close | 43.54 |
| Open | 39.67 |
| Bid | 40.34 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 39.67 - 40.39 |
| 52-week range | 33.78 - 48.18 |
| Volume | |
| Avg. volume | 216,558 |
| Market cap | 10.721B |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | 32.25 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
QIAGEN partners with FBI to develop digital PCR assay for QIAcuity for use in forensics
Collaboration aims to create novel digital PCR assay to improve successful results in DNA analysis from human samples for use in forensics and human identification // DNA quantification enables law enforcement and forensic researchers to analyze a broader range of evidence more quickly, accurately and reliably // Collaboration strengthens QIAGEN’s leading position in human identification and forensicsVenlo, the Netherlands, and Washington, D.C., May 07, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGE
- GlobeNewswire
QIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inherited disease applications
QCI Secondary Analysis a cloud-based software directly integrated with QCI Interpret, enabling high-throughput secondary analysis of clinical next-generation sequencing data // New software advances precision medicine by enabling smaller and decentralized labs to adopt NGS testing with efficiency, consistency and confidence // Combination of QCI Secondary Analysis and QCI Interpret provide a secure and compliant environment for trusted and scalable bioinformatics workflows for oncology and inher
- Globe Newswire
QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance
Q1 2024: Net sales of $459 million (-5% actual rates, -5% constant exchange rates, CER); diluted EPS of $0.36 and adjusted diluted EPS of $0.46 // Net sales at CER of $462 million ahead of outlook for at least $455 million CER and adj. diluted EPS of $0.47 CER ahead of $0.44 CER outlook // Excluding COVID-19 product groups, net sales decline 1% CER // Diagnostics sales +5% CER on double-digit CER growth in QuantiFERON and QIAstat‑Dx // 25.7% adjusted operating income margin on efficiency gains v
